12:00 AM
 | 
Jul 29, 2013
 |  BioCentury  |  Emerging Company Profile

Inflection: Pairing up PIM

Inflection combines pan-PIM kinase, PI3K, mTOR inhibitors in single molecule

Inflection Biosciences Ltd. is developing pan-PIM kinase inhibitors that are a few years behind large pharma competitors, but the biotech's compounds can be structurally linked to other kinase inhibitors for cancer. The small molecules thus could address multiple pathways with a single compound, simplifying combination therapy.

PIM kinases are a family of serine threonine kinases involved in cell cycle regulation, apoptosis, cell metabolism and metastases. Knockout mice with PIM1, 2 and/or 3 removed or silenced are viable and fertile, which is encouraging from a safety perspective, said Michael O'Neil, co-founder and director of R&D at Inflection.

PIM kinases are overexpressed in many hematologic and solid cancers, including pancreatic and esophageal cancer. High expression is associated with poor prognosis and treatment resistance.

Early work...

Read the full 601 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >